Hepatitis C: An update

Swiss Medical Weekly

Volumn 131, Issue 21-22, 2001, Pages 291-298

  Moradpour, D ^a   Cerny, A ^a   Heim, M H ^a   Blum, H E ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Helicase; Hepatitis C virus; Immunopathogenesis; Interferon ; Polymerase; Protease; Ribavirin

Indexed keywords

ANTIVIRUS AGENT;

CANCER RISK; CHRONIC HEPATITIS; DISEASE COURSE; DRUG TARGETING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; REVIEW;

EID: 0035795897     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Isolation ora cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
2. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
3. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium
4. Epidemiology of hepatitis C: Geographic differences and temporal trends
5. Hepatitis C - Global prevalence (update)
6. Hepatitis C-virus-infektion - Übersicht SEVHEP
7. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt
8. Transmission of the hepatitis C virus from a patient to an anesthesiology assistant to five patients
9. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
10. Virus taxonomy
11. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA
12. Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins
13. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line
14. Replication of hepatitis C virus
15. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties
16. Binding of hepatitis C virus to CD81
17. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor
18. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
19. Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance
20. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase
21. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site
22. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
23. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
24. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
25. A proposed system for the nomenclature of hepatitis C viral genotypes
26. National Institutes of Health consensus development conference panel statement: Management of hepatitis C
27. Consensus statement
28. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: Proposals for standardization
29. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence
30. Lack of protective immunity against reinfection with hepatitis C virus
31. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children
32. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif
33. Analysis of successful immune responses in persons infected with hepatitis C virus
34. Possible mechanism involving T lymphocyte response to non structural protein 3 in viral clearance in acute hepatitis C virus infection
35. Different clinical behaviors of acute hepatitis C virus infection arc associated with different vigor of the anti-viral cell-mediated immune response
36. Immnunology taught by viruses
37. Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation in vitro
38. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway
39. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition
40. Hepatitis C: The clinical spectrum of disease
41. Natural history of hepatitis C: Its impact on clinical management
42. 45-Year follow-up of hepatitis C virus infection in healthy young adults
43. Clinical outcomes after transfusion-associated hepatitis C
44. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
45. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study
46. Risk factors for the rising rates of primary liver cancer in the United States
47. Molecular pathogenesis of hepatocellular carcinoma
48. Extrahepatic manifestations of HCV infection: Facts and controversies
49. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA
50. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
51. The broad-spectrum antiviral rihonucleoside ribavirin is an RNA virus mutagen
52. Interferon-α inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway
53. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
54. Current therapy for chronic hepatitis C
55. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C
56. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
57. Peginterferon alfa-2a in patients with chronic hepatitis C
58. Long-term outcome of hepatitis C infection after liver transplantation
59. Neuc therapeutische Konzepte
60. Gene therapy for chronic viral hepatitis: Ribozymes, antisense oligonucleotides, and dominant negative mutants
61. Vaccination of chimpanzees against infection by the hepatitis C virus
62. DNA vaccine strategies for hepatitis C
63. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV